In the latest quarter, 5 analysts provided ratings for OrthoPediatrics (NASDAQ:KIDS), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 1 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.2, a high estimate of $30.00, and a low estimate of $20.00. This upward trend is evident, with the current average reflecting a 6.75% increase from the previous average price target of $22.67.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of OrthoPediatrics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Richard Newitter | Truist Securities | Raises | Hold | $20.00 | $19.00 |
| Mike Matson | Needham | Raises | Buy | $30.00 | $26.00 |
| Ryan Zimmerman | BTIG | Raises | Buy | $24.00 | $23.00 |
| Mathew Blackman | TD Cowen | Announces | Buy | $23.00 | - |
| Caitlin Roberts | Canaccord Genuity | Announces | Buy | $24.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to OrthoPediatrics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of OrthoPediatrics compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for OrthoPediatrics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into OrthoPediatrics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on OrthoPediatrics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering OrthoPediatrics: A Closer Look
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
A Deep Dive into OrthoPediatrics's Financials
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, OrthoPediatrics showcased positive performance, achieving a revenue growth rate of 12.23% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: OrthoPediatrics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -19.22%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): OrthoPediatrics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -3.34%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): OrthoPediatrics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.36%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: OrthoPediatrics's debt-to-equity ratio is below the industry average. With a ratio of 0.28, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Understanding the Relevance of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.